Drug intelligence / Profile preview

Blood Substitute (veterinary)

Development stage: Preclinical
Lead developer: NanoGroup
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Blood Substitute (veterinary) is a perfluorocarbon-based nano-emulsion developed by NanoGroup as a synthetic oxygen carrier for veterinary medicine. It is designed to function as a red blood cell replacement in animals suffering from acute blood loss. The mechanism of action relies on the high solubility of respiratory gases (oxygen and carbon dioxide) in perfluorocarbons, allowing the emulsion to transport and deliver oxygen to tissues independently of hemoglobin. This product is part of NanoGroup's NanOX platform, which focuses on respiratory gas transport systems, and is currently in the preclinical stage of development.

Other names: perfluorocarbon nano-emulsion (veterinary)NanOX (veterinary)

Beyond the preview

Go deeper on Blood Substitute (veterinary).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blood Substitute (veterinary).

Explore the full profile